

At page 56, line 20, delete "on" and insert --no--.

At page 57, line 1, delete "to" and insert --into--.

At page 57, line 2, delete "in" and insert --at--.

At page 57, line 23, after "afford" insert --compound 3--.

At page 58, line 24, delete "streptavidin" and insert --streptavidin--.

At page 60, line 11, after "prepared" delete --3--.

At page 60, line 20, delete "Panels A-C from Figure 4" and insert --Figures 4A-C--.

At page 61, line 26, delete "panels A-C in figure 5" and insert --Figures 5A-C--.

IN THE CLAIMS:


- ①⁵ 2. (Amended) A method for improving [increasing] the pharmacokinetic properties of VEGF Nucleic Acid Ligand in an ocular application comprising covalently linking a Non-Immunogenic, High Molecular Weight compound to a VEGF Nucleic Acid Ligand to form a complex comprised of a VEGF Nucleic Acid Ligand and a Non-Immunogenic, High Molecular Weight Compound.

REMARKS:

Claim 2 as allowed is directed to "a method of increasing the pharmacokinetic properties of a Nucleic Acid Ligand" however the activity would be more accurately described as "a method of improving the pharmacokinetic properties of a Nucleic Acid Ligand" Support for this amendment can be found on page 1, line 24; page 11, lines 24-25; and page 20, lines 7-12.

The Examiner is hereby encouraged to telephone the undersigned should there be any questions or concerns regarding this amendment.

Respectfully submitted,


Rosemary Kellogg, 759.726
Swanson & Bratschun, L.L.C.
8400 E. Prentice Avenue, Suite 200
Englewood, CO 80111
(303) 793-3333